Drugs / PTX-9908
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT03812874 | Oct 2020 → Aug 2026 overdue | hepatocellular carcinoma | TCM Biotech International Corp. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PTX-9908 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03812874 ↗ |
| Route | Intravenous | “administrated PTX-9908 Injection intravenously” NCT03812874 ↗ |